-
TRUSTED AU LABORATORY
-
26 Mark Rd. Elizabeth South, SA - 5112
-
Same day delivery
Pull the syringe to:
(0.100ml)
This calculator is provided as a reference tool for research purposes only. Always follow your institution’s safety protocols when handling research compounds.
CJC-1295 No DAC + Ipamorelin 10mg is a research peptide blend commonly studied in growth hormone secretagogue research. It combines two compounds that are often researched for their relationship with growth hormone signalling, peptide receptor activity and endocrine pathway studies.
CJC-1295 No DAC is commonly discussed as a short-acting growth hormone-releasing hormone analogue. Ipamorelin is studied as a selective growth hormone secretagogue receptor agonist. In research settings, the two are often examined together because they interact with different upstream pathways connected to growth hormone release.
This product is supplied for laboratory research use only. It is not a medicine, supplement, therapeutic product, cosmetic product or injectable product for human use.
| Product Detail | Information |
|---|---|
| Product name | CJC-1295 No DAC + Ipamorelin |
| Size | 10mg total vial content |
| Product type | Research peptide blend |
| Research category | Growth Hormone Research |
| Common research interest | Growth hormone secretagogue signalling |
| Form | Lyophilised powder |
| Intended use | Laboratory research only |
| Human use | Not for human consumption, administration or injection |
| Documentation | Certificate of Analysis should be checked before use |
| Component | Research Class | General Research Role |
|---|---|---|
| CJC-1295 No DAC | GHRH analogue | Studied for its relationship with growth hormone-releasing hormone receptor signalling |
| Ipamorelin | Growth hormone secretagogue | Studied for selective growth hormone secretagogue receptor activity |
| Lyophilised peptide preparation | Freeze-dried peptide format | Supports product stability before reconstitution when stored correctly |
The exact ratio of each component should always be confirmed through the product specification, supplier documentation or Certificate of Analysis. Researchers should not assume the composition of a peptide blend without reviewing batch-level documentation.
CJC-1295 No DAC and Ipamorelin are commonly studied within growth hormone secretagogue research. While both are linked to the growth hormone axis, they are not identical in how they are researched.
CJC-1295 No DAC is generally studied for its relationship with the GHRH pathway. This pathway is connected to growth hormone-releasing hormone receptor activity.
Ipamorelin is studied in relation to the growth hormone secretagogue receptor system. This pathway is commonly associated with ghrelin-related signalling and growth hormone pulse research.
When studied together, researchers are usually interested in how these two different signalling pathways may interact in controlled laboratory settings.
| Research Area | CJC-1295 No DAC | Ipamorelin |
|---|---|---|
| Main pathway | GHRH receptor pathway | Ghrelin / GHS-R pathway |
| Research category | Growth hormone-releasing hormone analogue | Growth hormone secretagogue |
| Common research interest | GH signalling pathway support | GH secretagogue receptor activity |
| Why studied together | Different upstream signalling pathway | Complementary secretagogue pathway |
| Important limitation | Research use only | Research use only |
| Common Online Claim | Safer Research-Use Wording |
|---|---|
| Muscle growth | Studied in relation to growth hormone and IGF-1 signalling pathways |
| Fat loss | Studied within metabolic and endocrine signalling research |
| Anti-ageing | Studied in growth hormone axis and cellular signalling models |
| Recovery | Studied in laboratory models connected to growth hormone biology |
| Sleep support | Studied in relation to endocrine rhythm and GH-related research pathways |
CJC-1295 No DAC + Ipamorelin 10mg is not intended to diagnose, treat, cure or prevent any disease. It is not supplied for body enhancement, weight loss, muscle growth, anti-ageing, recovery, sleep improvement, sexual performance or general wellness use.
All information on this page is provided for laboratory research and product handling context only.
There is no universal recommended dilution that applies to every research setting. Dilution depends on the research protocol, required working concentration, assay design, solvent compatibility, storage requirements and laboratory handling procedures.
For research concentration planning only, the basic formula is:
Total peptide amount divided by diluent volume equals final concentration.
| Diluent Added to 10mg Vial | Final Concentration |
|---|---|
| 1mL | 10mg/mL |
| 2mL | 5mg/mL |
| 2.5mL | 4mg/mL |
| 3mL | 3.33mg/mL |
| 4mL | 2.5mg/mL |
| 5mL | 2mg/mL |
| 10mL | 1mg/mL |
These are concentration examples only. They are not human dosing instructions and must not be used to calculate injection quantities.
Before handling CJC-1295 No DAC + Ipamorelin 10mg in a laboratory setting, make sure the required materials, documentation and clean handling conditions are ready.
| Item | Purpose |
|---|---|
| Product vial | Contains lyophilised CJC-1295 No DAC + Ipamorelin blend |
| Certificate of Analysis | Confirms batch-level testing information |
| Suitable research-grade diluent | Used to prepare a working research solution |
| Sterile lab consumables | Helps reduce contamination risk |
| Personal protective equipment | Gloves, lab coat and eye protection |
| Alcohol wipes or approved disinfectant | Used for surface and vial-top preparation |
| Laboratory labels | Records concentration, date, batch and handler details |
| Cold storage access | Supports correct storage after preparation |
| Disposal container | Used for compliant laboratory waste disposal |
The following is a general laboratory handling framework only. Always follow the product Certificate of Analysis, supplier documentation, SDS, institutional procedures and validated research protocol.
Check the product label, batch number, Certificate of Analysis and storage requirements before handling the vial.
Use a clean laboratory workspace. Wear appropriate PPE and disinfect the bench surface, vial top and any required equipment.
If the vial has been stored cold, allow it to equilibrate according to laboratory procedure before opening or reconstitution. Avoid condensation entering the vial.
Add the selected research-grade diluent slowly down the inside wall of the vial. Avoid forceful spraying directly onto the lyophilised powder.
Gently swirl or roll the vial until the powder is dissolved. Avoid aggressive shaking, unnecessary vortexing or foaming unless a validated protocol specifically allows it.
Check the solution for cloudiness, visible particles, unusual colour changes or undissolved material. If anything appears abnormal, quarantine the vial and check supplier documentation.
Label the vial or aliquots with the product name, concentration, diluent used, date prepared, batch number and researcher initials.
Place the reconstituted solution into the required storage condition as soon as possible. Avoid unnecessary warming, cooling or repeated freeze-thaw cycles.
Some lyophilised peptide products may take time to fully hydrate. Dissolution should always be handled gently and according to laboratory protocol.
| Issue | What It May Indicate | Safer Response |
|---|---|---|
| Powder clinging to vial wall | Static or lyophilisation residue | Allow more contact time with diluent |
| Small particles remain | Incomplete hydration | Continue gentle swirling |
| Cloudy solution | Possible incompatibility or contamination | Stop and check documentation |
| Foaming | Too much agitation | Let the solution settle and avoid shaking |
| Colour change | Possible degradation or contamination | Do not continue without supplier guidance |
| Storage Factor | Guidance |
|---|---|
| Product form | Lyophilised powder |
| Storage condition | Follow supplier label and Certificate of Analysis |
| Light exposure | Protect from unnecessary light exposure |
| Moisture exposure | Keep sealed until use |
| Temperature changes | Avoid repeated temperature cycling |
| Handling | Minimise unnecessary opening or vial puncture |
| Storage Factor | Guidance |
|---|---|
| Storage condition | Follow validated research protocol |
| Labelling | Record concentration, date, diluent and batch number |
| Freeze-thaw cycles | Avoid repeated freeze-thaw exposure |
| Aliquoting | Use small research aliquots where appropriate |
| Contamination control | Use clean laboratory technique |
| Disposal | Dispose according to laboratory waste procedures |
Peptides may be sensitive to temperature, light, pH, agitation and contamination. Storage conditions should be confirmed through supplier documentation or the laboratory’s validated method.
This page does not provide human dosing, injection instructions, injection schedules or administration guidance.
CJC-1295 No DAC + Ipamorelin 10mg is not supplied for human or animal administration. It is a laboratory research-use product only.
For research settings, any measured aliquots should be prepared according to the concentration required by the approved research protocol. All calculations should be checked, documented and traceable.
| Planning Item | What to Record |
|---|---|
| Final concentration | Total peptide amount and diluent volume |
| Working solution | Concentration used in the research protocol |
| Aliquot volume | Volume transferred into each labelled lab tube |
| Batch details | Product batch, CoA and preparation date |
| Storage location | Fridge, freezer or other controlled storage area |
| Handler details | Researcher name or initials |
| Preparation date | Date and time of reconstitution |
| Disposal date | When the aliquot should no longer be used |
Correct handling is important for research consistency, contamination control and product traceability. Most mistakes occur when products are not labelled clearly, concentration calculations are not recorded or storage conditions are not followed.
| Always | Why It Matters |
|---|---|
| Check the Certificate of Analysis | Confirms batch-level information |
| Use PPE | Reduces contamination and exposure risk |
| Label every vial and aliquot | Prevents mix-ups |
| Record concentration calculations | Supports traceability |
| Use clean laboratory technique | Reduces contamination risk |
| Follow institutional protocols | Keeps handling consistent and auditable |
| Store according to documentation | Helps protect peptide integrity |
| Dispose of lab waste correctly | Supports safety and compliance |
| Never | Why It Is Risky |
|---|---|
| Never use for self-injection | Product is research use only |
| Never make human dosing claims | Creates safety and compliance risk |
| Never assume purity without CoA | Batch quality must be documented |
| Never use a damaged or unlabelled vial | Identity and sterility may be uncertain |
| Never shake aggressively | May affect peptide integrity |
| Never use random solvents | May damage the peptide or alter research results |
| Never leave reconstituted product unlabelled | Creates traceability risk |
| Never rely on social media protocols | They may be inaccurate, unsafe or non-compliant |
The table below is for concentration planning only. It does not represent dosage, injection quantity or recommended administration.
| Total Vial Amount | Diluent Volume | Final Concentration |
|---|---|---|
| 10mg | 1mL | 10mg/mL |
| 10mg | 2mL | 5mg/mL |
| 10mg | 2.5mL | 4mg/mL |
| 10mg | 3mL | 3.33mg/mL |
| 10mg | 4mL | 2.5mg/mL |
| 10mg | 5mL | 2mg/mL |
| 10mg | 10mL | 1mg/mL |
If a researcher adds 2mL of suitable research-grade diluent to a 10mg vial, the resulting concentration is 5mg/mL.
This calculation is for research concentration planning only. It is not a human or animal dosing example.
No. CJC-1295 No DAC is generally used to describe a shorter-acting GHRH analogue research product. CJC-1295 with DAC refers to a DAC-linked form designed for extended activity in research contexts. Product identity should always be confirmed through supplier documentation and analytical testing.
They are commonly studied together because they relate to different signalling pathways connected to growth hormone research. CJC-1295 No DAC is associated with the GHRH pathway, while Ipamorelin is associated with the growth hormone secretagogue receptor pathway.
No. This product is supplied for laboratory research use only. It should not be described as approved for therapeutic, cosmetic, body enhancement or injectable use.
No. This product should not be promoted for weight loss, muscle growth, anti-ageing, performance enhancement, recovery, sleep improvement or general wellness outcomes.
A Certificate of Analysis provides batch-level testing information. It helps researchers verify product identity, purity and quality documentation before use in a research setting.
| Resource | Why It Is Useful |
|---|---|
| TGA guidance on unapproved peptide products | Important Australian regulatory context for peptide products, advertising and supply responsibilities |
| TGA warning on importing unapproved peptides | Explains safety concerns around poorly labelled peptide powders and injectable products |
| PubMed research on CJC-1295 | Useful background on controlled research involving CJC-1295 and GH/IGF-1 signalling |
